Aqueous Emulsion Solubilization via TPGS and Linoleic Acid Blend
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The oral delivery of oily, water-insoluble nutraceutical compounds like vitamin E is challenging due to poor absorption by the gastrointestinal tract, and existing aqueous emulsions face limitations in stability and dosage size, especially for patients with malabsorption conditions, where high concentrations of solubilizing agents like TPGS are costly and can lead to overdosing.
Innovation Solution
An aqueous emulsion comprising a blend of TPGS and linoleic acid, which improves the solubilization of lipophilic compounds, allowing for higher concentrations and a broader range of lipophiles, including all eight vitamin E homologs, without increasing the dosage size beyond 4 teaspoons (20 mL), by acting as a co-emulsifier and reducing the required amount of TPGS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If TPGS is used as a solubilizing agent in aqueous emulsion, then the solubilization of lipophilic compounds is improved, but the dosage size increases beyond acceptable limits
Solution Approach 1:
The patent combines TPGS with linoleic acid to create a composite solubilizing system. This composite approach allows the formulation to achieve higher lipophile loading (up to 20% w/v) without proportionally increasing the dosage size, as the linoleic acid enhances the solubilizing capacity per unit volume of the emulsion.
Solution Approach 2:
The patent modifies the chemical composition parameters of the solubilizing phase by incorporating linoleic acid alongside TPGS. This parameter change enables the system to accommodate higher concentrations of lipophilic compounds while maintaining acceptable dosage volumes under 20 mL.
2Quantity of substance
If TPGS is used as a solubilizing agent in aqueous emulsion, then the solubilization of lipophilic compounds is improved, but the cost increases due to the expensive material
Solution Approach 1:
Linoleic acid serves as an intermediary substance that enhances the solubilizing efficiency of TPGS. By introducing this intermediate agent, the formulation achieves higher lipophile concentrations without requiring proportionally more expensive TPGS, thus reducing the overall cost burden.
Solution Approach 2:
The patent incorporates linoleic acid, a relatively inexpensive substance, to augment the solubilizing system. This allows the formulation to achieve high lipophile loading while minimizing the use of costly TPGS, effectively replacing some expensive material with a cheaper alternative.
3Quantity of substance
If excess TPGS is used for solubilization, then the solubilization capacity increases, but vitamin E overdose occurs
Solution Approach 1:
Linoleic acid acts as a mediator that shares the solubilization burden with TPGS. This intermediary role allows the system to achieve the required solubilization capacity with reduced TPGS content, thereby preventing vitamin E overdose while maintaining adequate solubilization of lipophilic compounds.
Solution Approach 2:
The patent employs partial action by using sub-maximal amounts of TPGS combined with linoleic acid. This partial approach to solubilization is sufficient to achieve the desired lipophile concentration while avoiding the harmful effects of excessive TPGS and vitamin E.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The emulsion achieves a therapeutically effective concentration of lipophiles at a lower TPGS dosage, enhancing stability and potency, enabling a higher concentration of multiple lipophiles in a smaller, more manageable dosage form, while minimizing vitamin E overdose risks.
Implementation Method 1
the lipophile is solubilized and dispersed throughout the aqueous phase via a solubilizing agent
Implementation Method 2
A desirable oral dosage form for administering water-solubilized lipophiles is an aqueous oil-in-water emulsion
Implementation Method 3
it is necessary to limit the amount of the solubilized active lipophile in the emulsion to maintain stability so that the lipophilic dispersed phase remains homogeneously distributed throughout the aqueous continuous phase
Data Source
AI summary
Disclosed herein is an aqueous emulsion. The lipid phase of the emulsion includes a blend of a therapeutically effective concentration of a lipophile, a concentration of Vitamin E TPGS, and a concentration of linoleic acid. The presence of linoleic acid increases the solubilizing affect of Vitamin E TPGS on the lipophile and thus reduces the amount of Vitamin E TPGS that would otherwise be required in the aqueous emulsion.